The next generation of highly immunodeficient mice is helping researchers generate PDX and CDX models. One of the most promising new models is the B-NDG mouse.
In one recent study, the B-NDG model was superior to athymic mice in supporting NSCLC human tumor cell growth. This model is ideal for testing anti-cancer agents for their ability to delay tumor growth. Another recent study showed that B-NDG mice were superior to the JAX® NSG™ mice for CDX model development using the Kasumi-1 human tumor cell line.
Complete the form to request our case study and gain more insight.
JAX® is a registered trademark and NSG™ is a trademark of The Jackson Laboratory.
